- 1 Administration of *Bifidobacterium animalis* subsp. *lactis* Strain BB-12[®] in
- 2 Healthy Children: Characterization, Functional Composition, and
- 3 Metabolism of the Gut Microbiome
- 4 Carlotta Vizioli^{1,2}, Rosario Jaime-Lara^{2,3,4}, Scott G. Daniel⁵, Alexis Franks³, Ana F.
- 5 Diallo⁶, Kyle Bittinger^{5,} Tina P. Tan⁷, Daniel J. Merenstein⁷, Brianna Brooks³,
- 6 Paule V. Joseph*^{2,3}, Katherine A. Maki⁸*
- 7
- 8
- 9¹ National Institute of Neurological Disease and Stroke, National Institutes of Health,
- 10 Department of Health and Human Services, Bethesda, MD
- ² National Institute on Alcohol Abuse and Alcoholism National Institutes of Health, Department
 of Health and Human Services, Bethesda, MD
- ³ National Institute of Nursing Research, National Institutes of Health, Department of Health and
 Human Services, Bethesda, MD
- ⁴ UCLA School of Nursing, University of California Los Angeles, Los Angeles, CA
- ⁵ Division of Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia,
 Philadelphia, PA
- ⁶ Institute of Inclusion, Inquiry & Innovation (iCubed), Family and Community Health Nursing,
- 19 School of Nursing, Virginia Commonwealth University, Richmond, VA
- ⁷ Department of Family Medicine, Georgetown University Medical Center, Washington, DC
- 21 ⁸ Translational Biobehavioral and Health Disparities Branch, National Institutes of Health,
- 22 Clinical Center, Bethesda, MD, 20814
- 23 *PVJ and KAM are co-senior authors.
- 24 Corresponding Author: Paule V. Joseph, Ph.D., MS, FNP-BC, CTN-B, National Institute of
- 25 Nursing Research, National Institutes of Health, Department of Health, and Human Services, 1
- 26 Cloister Court, Bldg 60 Rm 270, Bethesda, MD 20892; paule.joseph@nih.gov
- 27
- 28 Manuscript Word Count:
- 29 Tables/Figures: 1/7

30 Abbreviations

31	FC	Fold Change
32	FDR	False Discovery Rate
33	GI	Gastrointestinal
34	PCA	Principal Component Analysis
35	PCoA	Principal Coordinate Analysis
36	PERMANOVA	Permutational Analysis of Variance
37	RA	Relative Abundance
38 39	S2	Two-strain (Streptococcus thermophilus and Lactobacillus delbrueckii) Yogurt Group
40 41	S2+BB12	Two-strain (Streptococcus thermophilus and Lactobacillus delbrueckii) plus Bifidobacterium animalis subsp. lactis strain BB-12 Yogurt Group
42	TMAO	Trimethylamine N-oxide
43		
44		
45	Keywords: probiotic	s; gut microbiome; L. delbrueckii; B. animalis BB-12; S. thermophilus;
46	metagenomics; metal	bolomics, children
47		
48	Trial Registration: 1	NCT001652287
49		

50 Abstract

51 The consumption of probiotics may influence children's gut microbiome and metabolome, which 52 may reflect shifts in gut microbial diversity composition and metabolism. These potential 53 changes might have a beneficial impact on health. However, there is a lack of evidence 54 investigating the effect of probiotics on the gut microbiome and metabolome of children. We 55 aimed to examine the potential impact of a two (Streptococcus thermophilus and Lactobacillus 56 delbrueckii; S2) vs. three (S2 + Bifidobacterium animalis subsp. lactis strain BB-12) strain-57 supplemented yogurt. Included in this study were 59 participants, aged one to five years old, 58 recruited to phase I of a double-blinded, randomized controlled trial. Fecal samples were 59 collected at baseline, after the intervention, and at twenty days post-intervention discontinuation, 60 and untargeted metabolomics and shotgun metagenomics were performed. Shotgun 61 metagenomics and metabolomic analyses showed no global changes in either intervention 62 group's gut microbiome alpha or beta diversity indices. The relative abundance of the two and 63 three intervention bacteria increased in the S2 and S2 + BB12 groups, respectively, from Day64 0 to Day 10. In the S2+BB12 group, the abundance of several fecal metabolites was reduced 65 at Day 10, including alanine, glycine, lysine, phenylalanine, serine, and valine. These fecal metabolite changes did not occur in the S2 group. Future research using longer probiotic 66 67 intervention durations and in children at risk for gastrointestinal disorders may elucidate if 68 functional metabolite changes confer a protective gastrointestinal effect. 69 70 71 72 73 74 75 76 77

78 Introduction

79 The gut microbiome is comprised of the entire gastrointestinal (GI) microbial 80 community, including bacteria, fungi, viruses, and their genes. Metagenomic analysis captures a 81 comprehensive summary of the microbiome, *i.e.*, microbial diversity and their ecological niches 82 (microbial function). [1] Gut colonization starts prenatally and continues after birth. The gut 83 microbiome in early infancy begins to stabilize early in life. [2] Several mechanisms, including 84 birth mode, [3] type of milk received, [4] and environmental factors, [5] shape the development 85 of the gut microbiome from infancy to adulthood. The environment and diet during the first two 86 to five years turn an immature microbiota into a more stable, resilient, adult-like gut microbial community. [5] The human gut microbiome influences nutritional absorption, immune health, 87 88 and behavior. [6] Pre-clinical and clinical studies suggest that the gut microbiota-immune system 89 crosstalk may be responsible for long-term health. [7, 8] Disruptions to a healthy gut microbiome 90 are observed during disease states and across chronic illnesses, including inflammatory and 91 immune disorders. [9-11] 92 Probiotics are defined by the International Scientific Association for Probiotics and 93 Prebiotics as "live microorganisms that, when administered in adequate amounts, confer a health 94 benefit on the host". [12] Probiotics are increasingly used in commercial products because of 95 their potential benefits on the gut microbiota that have been shown to exert positive effects on 96 host physiology. [12, 13] The mechanism of action by which probiotics confer health benefits are 97 diverse and include: colonization and normalization of perturbed intestinal microbial

98 populations, competitive exclusion of pathogens, and modulation of the immune system via

99 production of anti-inflammatory factors. [14]

100	Probiotics have been used in treatment of GI symptoms and prevention or management of
101	GI disorders. Several studies have shown that probiotic strains from the Bifidobacterium genus
102	promote the growth of beneficial bacteria, inhibit pathogenic microorganisms by secreting
103	antibacterial factors, [15] competitive adhesion to intestinal epithelial cells [14] improve GI
104	barrier, [16, 17] promoting the formation of mucous layers maintaining of intestinal immune
105	homeostasis, [18] and lower inflammatory cytokines. [19] Moreover, consumption of
106	Lactobacillus and Bifidobacterium genera have been associated with improved mental health and
107	memory function in pre-clinical and human studies. [20-23]
108	There is increasing interest in using probiotics as a tool to maintain and restore a healthy
109	gut microbiota. While evidence supports their use in some GI diseases, the impact of probiotics
110	on healthy gut microbiota and its metabolism is still unclear in both adults and children. [24-27]
111	Few studies have examined the effect of probiotics in healthy adults, [26-28] and even fewer
112	have studied the effect of probiotics in healthy children. [29] Although Bifidobacterium animalis
113	subsp. lactis BB-12 (BB-12) is among the most common probiotic supplements and has
114	previously been demonstrated to be well-tolerated by healthy children, [30] there are limited
115	studies examining the effects of BB-12 on structural and functional characteristics of the gut
116	microbiome in children ages one to five years old. [30]
117	Metabolites produced by gut microorganisms have been identified in modulating human
118	health, including the immune system, metabolic, and neurobehavioral traits. [14, 21, 28, 31, 32]
119	Furthermore, emerging studies suggest that probiotics' effects on intestinal metabolites may
120	contribute to intestinal health and immune function. [32-36] Thus, there is growing interest in the
121	link between probiotic administration and the subsequent impact on metabolite changes in the
122	context of human health and disease. Shotgun metagenomics sequencing and untargeted

metabolomics technologies have grown exponentially in the last decade providing a key tool to closer examine the microbial characterization, function, and metabolism in a sample (*e.g.*, fecal or tissue samples). Therefore, metabolomics offers an efficient and accurate strategy of exploring the biological role of how probiotics may impact the pediatric gut microbiome, including how these metabolites respond to different combinations of symbiotic bacteria administration (i.e.,

128 Bifidobacterium vs. Lactobacillus spp. probiotic genera). [37]

129 Exploring the effect of probiotics on the gut microbiome and metabolome in healthy 130 children may provide more extensive insight into the relationship between probiotics, gut 131 microbiota, metabolites, and human health. This may aid in developing more effective methods 132 of assessing gut health by simultaneously characterizing the gut microbiome and functional 133 impacts of microbiome community changes on the metabolome. Furthermore, GI disorders are 134 among the most common ailments reported in pediatric primary care. Therefore, utilizing our 135 approach including microbiome and metabolome analyses to characterize structural and 136 functional responses of gut microbiota to two probiotics combinations (Streptococcus 137 thermophilus and Lactobacillus delbrueckii [S2] vs. Streptococcus thermophilus, Lactobacillus 138 delbrueckii, and Bifidobacterium animalis subsp. lactis strain BB-12 [S2+BB12]) in children is 139 an important first step to design future research evaluating the efficacy of probiotics in the 140 prevention of dysbiosis-associated GI disorders.

141 To date, few studies have been conducted to examine the effect of probiotics on gut 142 microbial compositional and functional structure combined with associated fecal metabolome 143 changes in healthy children. Thus, this study uses shotgun metagenomic sequencing and 144 untargeted fecal metabolomics to examine the effects induced by the consumption of yogurt with 145 and without the BB-12 probiotic strain (BB12) in healthy children aged one to five years old.

- 146 This study builds upon findings by Tan et al. [30] using shotgun metagenomics sequencing for
- 147 microbiome analysis and the integration of metabolomic data.
- 148 **Results**
- 149 **Participant Characteristics**
- 150 A total of 59 healthy participants between the ages of one and five years (mean age
- 151 $=2.38\pm1.22$) were included in the study (Figure 1A). The yogurt was administered to the
- 152 participants for ten consecutive days. Fecal samples were analyzed at baseline (Day 0), ten (Day
- 153 10), and 30 (Day 30) days from both S2+BB12 (n = 25, 28, and 25, respectively) and S2 (n = 31, day
- 154 30, and 30, respectively) groups (Figure 1B).



155

156 Figure 1: Study Design: A total of 59 children, aged one to five years old, were analyzed for this double-157 blinded, randomized controlled study (A). The participants consumed yogurt with two (S2 group) vs. 158 three (S2+BB12 group) probiotics' strains (B). The participants consumed vogurt during ten consecutive

159 days. Fecal samples were collected before the intervention (Day 0), after ten days of yogurt consumption

- 160 (Day 10), and after ten days of yogurt consumption discontinuation (Day 30).
- 161

162

Participants were relatively divided equally between males and females (n = 28 males

163 and n = 31 females). Most of the participants included were White (n = 40). Additional

164 demographic information from the included participants is displayed in Table 1.

165

		Overall	S2	S2+BB12
		n=59	n=31	n=28
A		2.38	2.42	2.35
Age	Mean (SD)	(1.22)	(1.21)	(1.26)
Gender (n)	Male	28	13	15
Gender (II)	Female	31	18	13
	Indian/Alaskan	1		1
	Back or African	8	4	4
Race (n)	White/Caucasian	40	17	23
	Other/more than one race	7	6	1
Ethnicity				
(n)	Hispanic/Latino	8	5	3

Table 1. Participants demographics

168 Metagenomic analyses

169 The administration of BB-12, in addition to S. thermophilus and L. delbrueckii, 170 influenced the composition of the gut microbiome, although there were no overt global 171 microbiome changes quantified by alpha and beta diversity indices. Species richness and 172 Shannon indices were not significantly different between the S2 and S2+BB12 groups at Day 10 173 (p = .565 and p = .462, respectively) or Day 30 (p = .669 and p = .104, respectively; Figure 2A-174 B). Similarly, there were no group differences in beta diversity (based on Bray-Curtis 175 dissimilarity) at Day 10 ($R^2 = 0.02$, p = .318; Figure 2C) or Day 30 ($R^2 = 0.02$, p = .3537; Figure 176 S1). These findings agree with previously reported results by Tan et al. using 16S rRNA analysis 177 [30]. 178 We built upon these findings by using shotgun metagenomics, which allowed us to 179 observe differential abundant taxa at the species level. As expected, the metagenomic analysis 180 showed an increase of *B. animalis* in the S2+BB12 group. *B. animalis* abundance was

181 significantly impacted by the administration of the BB12 supplemented yogurt (group \times time p <

182	.001; Figure 2D). We observed an effect of time, but not group, in <i>L. delbrueckii</i> (time $p < .001$;
183	group $p = .405$). S. thermophilus's relative abundance were significantly different in time and
184	group x time interaction (time $p < .001$; group $p = .349$; group x time $p = .020$) (Figure 2E-F). As
185	expected, post hoc testing showed in the S2+BB12 group a statistically significant increase
186	comparing Day 0 vs. Day 10 in BB-12 ($p < .001$), S. thermophilus ($p < .001$), and L. delbrueckii
187	(p = .018) abundances. Similarly, <i>Day 10 vs. Day 30</i> comparison showed a statistically
188	significant decrease in BB-12 ($p < .001$), S. thermophilus ($p = .001$), and L. delbrueckii ($p = .001$)
189	.004) abundances (Figure 2D-F). In the S2 group, we found statistically significant differences in
190	<i>Day 0 vs. Day 10</i> comparison of <i>S. thermophilus</i> ($p < .001$) and <i>L. delbrueckii</i> ($p = .005$)
191	abundances. Interestingly, BB-12 increased comparing Day 0 to Day 30 in the same group ($p =$
192	.016).
193	We then focused our analyses on within-group differences in both groups from $Day 0$ to
194	Day 10, as both groups received a probiotic intervention (S2 vs. S2+BB12) and were healthy
195	children. The 25 taxa with the greatest change in relative abundance between Day 0 and Day 10
196	were evaluated in order to observe the effect on individual microbial taxa following a ten-day
197	administration of two (S2) vs. three (S2+BB12) strains of probiotics. In addition to the
198	intervention bacteria that changed in the S2+BB12 group, we observed that the mean relative
199	abundance was lower than the control group for seven taxa belonging to Prevotella genus,
200	though the difference was not statistically significant after correction for multiple comparisons:
201	<i>P. intermedia</i> ($p = .999$), <i>P. melaninogenica</i> ($p = .574$), and <i>P. jejuni</i> ($p = .444$) (Figure 2G,
202	Supplemental Table 1). Other top changing bacteria S2+BB12 group were decreased relative
203	abundance in bacterial species from Day 0 to Day 10, but they did not remain statistically

204	significant after FDR correction including <i>I. butyriciproducens</i> ($p = .999$), <i>Enterobacter sp. FY</i> -
205	07 ($p = .999$), and <i>P. asaccharolytica</i> ($p = .999$; Figure 2H, Supplemental Table 1).
206	When we analyzed the differential abundance of gene orthologs, we found that the
207	relative abundance of the glucan 1,4-alpha-glucosidase and response regulator HydG genes
208	decreased from Day 0 to Day 10 in both groups, (Figure 2I-J). These differences were also not
209	statistically significant before or after FDR correction (Supplemental Table 1). Except for one
210	ortholog (fatty acid synthase [K11533]), all the 25 top changing gene orthologs were decreased
211	in the S2 group after ten days of probiotics administration, although these decreases were not
212	statistically significant (Figure 2I). An overall trend of decreased orthologs relative abundance
213	from Day 0 to Day 10 was similar in the S2+BB12 group, except for eight orthologs that had a
214	non-statistically significant increase following BB12 administration (Figure 2J).



Figure 2: Observed species (A) and Shannon (B) alpha diversity indices showing no differences comparing S2 (blue) and S2+BB12 (red) groups. PCoA based on Bray-Curtis dissimilarity followed by a PERMANOVA (*p*=.318) showing no separation among samples. Relative abundances of the three strains used in the S2 and S2+BB12 interventions: *B animalis* (D), *S. thermophilus* (E), and *L. delbruekii* (F) during time comparing S2 (blue) and S2+BB12 groups (red). Top 25 changing taxa (G-H) and gene orthologs (I-J) between *Day 0* and *Day 10* in S2 (G-I) and S2+BB12 (H-J) groups identified by linear model.

224

225 We selected 18 known probiotic strains identified through literature search (Supplemental 226 Table 2), to observe if the administration of two (S2) vs. three (S2+BB12) probiotic strains 227 would influence the abundance other known probiotics. Most of the identified probiotic-228 associated taxa belonged to Lactobacillus, Bacteroides, and Bifidobacterium genera, and were commonly used as probiotic supplements in the food industry or clinical trials (see Supplemental 229 230 Table 2 for references). We observed that the abundance of targeted probiotic-associated bacteria 231 increased from Day 0 to Day 10 in 61% (11/18) of selected taxa in the S2 group (Figure 3A) and 232 72% (13/18) of taxa in the S2+BB12 (Figure 3B) group, but most of the differences did not reach 233 statistical significance. Nevertheless, cumulative bacterial responses changes of probiotic-234 associated bacteria differed according to intervention group. For example, we observed no 235 pattern in samples distribution in the S2 group (Figure 3C), while in the S2+BB12 group we can 236 observe a separation of Day 0 vs. Day 10 samples (Figure 3D). In the S2+BB12 group, many of 237 the Day 10 probiotic-associated bacteria clustered with B. animalis, indicating similar response 238 to the probiotic (Figure 3D).



239

240 Figure 3: Relative abundances of selected probiotic taxa are plotted in S2 (A) and S2+BB12 (B) 241 groups after ten days of probiotic intervention (Day 0 vs. Day 10). Post-selection PCA shows selected 242 probiotics following ten days of probiotics administration in S2 (C) and S2+BB12 (D) groups. The 243 difference in S. thermophilus and B. animalis between Day 0 and Day 10 abundances are statistically 244 significant different (p < .0001 for both) in S2+BB12 group. Day 10 is represented by the darkest color all 245 plots. In PCA, different arrows colors refer to different genera: Blue, light blue, dark green, and green 246 represent Bifidobacterium, Lactobacillus, Bacteroides, and Streptococcus genera respectively. Each arrow 247 points in the direction of the steepest increase of the values for the corresponding feature. The angle 248 between arrows indicates the correlation between the different features (positive when the angle is sharp 249 and negative when the angle is larger than 90 degrees). The length of the arrow is a measure of fit for the 250 feature.

251

252 Metabolomic analyses

253 The untargeted metabolomic analysis identified 734 metabolites. To evaluate the impact

- of S2 vs. S2+BB12 probiotics on the metabolome, we performed both exploratory analyses
- 255 quantifying differences in all annotated metabolites and hypothesis-driven metabolomics
- analyses focused on amino acid-associated and short chain fatty acid metabolites.

257	After excluding xenobiotics, we conducted exploratory metabolomic analyses on 601
258	biochemicals. We analyzed the differences between Day 0 vs. Day 10, Day 10 vs. Day 30, and
259	Day 0 vs. Day 30 within the S2 and S2+BB12 groups (Supplemental Table 3). Metabolites
260	changes [t-test (raw <i>p</i> -value=.05) and FC analysis (threshold = 2)] comparing Day 0 vs. Day 10
261	and Day 0 vs. Day 30 in S2 (Figure 4A, C, E) and S2+BB12 (Figure 4B, D, F) groups are
262	presented. We found greater changes in the S2+BB12 group compared to the S2 group (14 vs.
263	three metabolites). After ten days of yogurt consumption, we found an increase of N-acetylvaline
264	(raw $p=.022$ FC=2.151) and a decrease of arachidoylcarnitine (C20) * (raw $p=.045$ FC=.436) and
265	nicotinate ribonucleoside (raw $p=.009$ FC=.326). Day 0 vs. Day 30 comparison exhibited several
266	changes in lipids decreased at Day 30 belonging to diacyglicerol metabolism: linoleoyl-
267	linoleoyl-glycerol (18:2/18:2) [1]* (raw p =.016 FC=0.29), palmitoyl-linoleoyl-glycerol
268	(16:0/18:2) [2]* (raw p=.009 FC=.311), palmitoyl-linoleoyl-glycerol (16:0/18:2) [1]* (raw
269	<i>p</i> =.008 FC=.263), oleoyl-linoleoyl-glycerol (18:1/18:2) [2] (raw <i>p</i> =.007 FC=.295), palmitoyl-
270	oleoyl-glycerol (16:0/18:1) [2]* (raw p =.004 FC=.252), and oleoyl-linoleoyl-glycerol (18:1/18:2)
271	[1] (raw $p=.002$ FC=0.221). The glycerolipids 2-palmitoyl-galactosylglycerol (16:0)* (raw
272	p<.001 FC=2.358) and 1-palmitoyl-galactosylglycerol (16:0)* (raw p =.001 FC=2.319), were
273	increased together with 3-hydroxybutyrate (BHBA) (raw $p=.022$ FC=2.821). Comparing Day 10
274	vs. Day 30, we found adenine decreased at Day 30 (raw $p=.023$ FC=0.48).
275	In the S2 group, the amino acid (R)-salsolinol was decreased after ten days of
276	intervention (Day 0 vs. Day 10) (raw $p=.01$ FC=.38) and 20 days after yogurt consumption
277	discontinuation (<i>Day 0 vs. Day 30</i>) (raw $p=.023$ FC=.423). Lactate and indolelactate were also
278	decreased looking at Day 0 vs. Day 30 comparison (FC=0.222, raw p=.045 and FC=0.165, raw

p=.022, respectively). PCA of untargeted metabolites showed no separation between the time



281



282

Figure 4: Volcano plot (p < .05, FC>2) comparing *Day 0 vs. Day 10* (**A**, **B**), *Day 0 vs. Day 30* (**C**, **D**), and *Day 10 vs. Day 30* (**E**, **F**) within S2 and S2+BB12 respectively. Metabolites in red/blue represent metabolites increased/decreased at *Day 10* (**A**, **B**) and *Day 30* (**C**-**F**).

286

Next, we focused on evaluating differences in specific metabolites associated with amino acid metabolism or biosynthesis, as we hypothesized that they would be impacted by probiotic intervention and associated with the gut microbiome in both groups. There were several aminoacid associated metabolites that differed as a result of time in both groups (Supplemental Table 4) including 3-methyl-2-oxobutyrate (p=.004), 3-methyl-2-oxovalerate (p=.025), alanine

- (p=.001), glutamate (p=.034), isoleucine (p=.020), and valine (p=.004), among others.
- 293 Conversely, glycine (p=.025), indolelactate (p=.034), N-acetylserine (p=.049), and
- 294 pyroglutamine (*p*=.007) had significant group x time effects as a result of the S2 and S2+BB12
- probiotic interactions (Supplemental Table 4). In the S2+BB12 group, average fecal metabolite
- abundances of 4-methyl-2-oxopentanoate, alanine, cysteine s-sulfate, glycine, histidine, lysine,
- 297 N-acetylalanine, N-acetylglutamine, N-acetylleucine, phenylalanine, serine and valine were
- significantly lower at Day 10 (versus baseline Day 0; Figure 5 A-N). Alanine, glycine, and N-
- acetylglutamine metabolite levels continued to be lower twenty days after the S2+BB12
- 300 probiotic was discontinued (Day 30) versus baseline (Figure 5B, D, H), while fecal cysteine s-
- 301 sulfate levels increased back to baseline levels after probiotic discontinuation.



303

Figure 5. Targeted metabolomic analysis on amino acids was used to study the differences comparing
Day 0 vs. Day 10, Day 0 vs. Day 30, and Day 10 vs. Day 30 within S2 (blue) and S2+BB12 (red) groups.
Linear mixed-effects model followed by post hoc pairwise testing with Tukey's correction (when
appropriate) were performed. All mixed model results of selected amino acid-associated metabolites and
post hoc testing results (when group, time, or group * time model results were significant) are listed in
Supplemental Table 3.

311 Integration of Metagenomics and Metabolomics Datasets

- 312 Microbe-metabolite interactions were tested through correlation matrices and visualized
- 313 with network graphs. After filtering, 26 microbial taxa and 79 metabolites were tested for
- 314 associations (Figure 6, Supplemental Table 5-6).



316 Figure 6: Heatmap representing FDR corrected correlations between microbial taxa and metabolites in S2

- and S2+BB12 groups. Red and blue represent negative and positive correlations respectively. Stars
- 318 indicate FDR values: * = FDR < .05, ** = FDR < .01, and *** = FDR < .001.
- 319

320	Metabolites that were significantly positively correlated with Enterobacteriaceae and
321	Escherichia coli included trimethylamine N-oxide (TMAO), ursodeoxycholate, 7-
322	ketodeoxycholate, and glycine (Figure 7). Other taxa that had multiple significant positive
323	associations with metabolites included Akkermansia muciniphila, Eubacterium hallii, Roseburia
324	hominis, and Clostridiales. Of the supplemented probiotic bacteria, B. animalis was positively
325	associated with uracil, S. thermophilus with deoxycarnitine and phenylalanine, and L. delbrueckii
326	with thymine. Known products of bacteria such as nicotinate (vitamin B3), pantothenate (vitamin
327	B5) correlated positively with Clostridiales, R. hominis, F. prausnitzii, and E. eligens (Figure

328 7A).



329

Figure 7. Significant microbial taxa and metabolite associations: Network analyses in samples across
Day 0, Day 10, and Day 30 within S2 and S2+BB12 groups. A. Network generated from microbial taxa
(ellipses) that passed filtering and microbial-associated metabolites (diamonds) identified from previous
work [38] showing only positive correlations. B. Same network but showing only negative correlations.
Width of edges is proportional to Spearman correlation coefficient and edge color is mapped to the FDR
value or the correlation test. All correlations between selected taxa and metabolites and statistical
significance testing results are listed in Supplemental Table 5.

337

338 Several amino acids correlated negatively with *F. prausnitzii* and *R. hominis*, including

339 glutamine, lactate, threonine, tryptophan and TMAO (Figure 7B). Lactate was also negatively

340 associated with A. rectalis, R. bicirculans, E. hallii, and Clostridiales; glucose with R.

341 *bicirculans*, *E. hallii*, and *A. muciniphila*; and glycerate with *A. muciniphila* and *B. longum*.

342 Among the probiotics of interest, *B. animalis* correlated negatively with arginine and *L*.

343 *delbrueckii* with 1-palmitoyl-GPE (16:0). Uracil was positively associated with Clostridiales, A.

344 *finegoldii*, and *E. rectale*. Uracil was also negatively correlated with *B. dorei*, *F. plautii*,

345 Enterobacteriaceae and *E. coli*.

346

347 **DISCUSSION**

348 This randomized, controlled study aimed to observe the differences following the 349 administration of yogurt supplemented with two (S2) vs. three (S2+BB12) probiotic strains in 350 healthy children. We studied probiotics consumption effects on the fecal microbiome and 351 metabolome comparing baseline, post-ten days (Day 10), and post-30 days (Day 30) following 352 vogurt administration. There were no significant differences in the global metagenomic or 353 metabolomic profiles between healthy children receiving two (S2) vs. three (S2+BB12) probiotic 354 strains for 10 days. Nevertheless, we observed a significant increase (Day 0 to Day 10) in the 355 relative abundance of the two and three probiotics administered in the S2 and S2+BB12 groups, 356 respectively, indicating the intervention had a measurable impact on the bacteria of interest in the 357 gut microbiome. Interestingly, in the S2 group, S. thermophilus species appear to maintain a 358 sustained increase over time, maintaining the significant increase in relative abundance from Day 359 0 vs. Day 30 As both cohorts of children received a probiotic cocktail and the intervention lasted 360 over a short period of time, the lack of strong association between groups in global microbiome 361 changes is not surprising and suggests a resilient and stable gut microbiota in this cohort of 362 healthy children ages one to five. Nevertheless, existing literature reports about infant's and

children's gut microbiota stability are conflicting. [39] [2] Infant and children's gut microbiota
are thought to be immature and therefore more susceptible to perturbations. In line with other
studies [40, 41] our data show short-term effects of probiotic administrations in both groups on
the gut microbiome and metabolome. The children's gut microbiota stability observed in this
study is consistent with the parent study's findings. [30]

368 Most studies examining the health benefits of probiotics have focused on people with 369 pathologies. However, few studies have examined the effects of probiotics on healthy individuals 370 and even fewer have examined the use of probiotics in children. A review of probiotic 371 supplementation in healthy adults found that probiotic supplementation led to a transient increase 372 in the concentration of supplement-specific bacteria but failed to support the ability of probiotics 373 to cause persistent changes in gut microbiota. [42] This is consistent with our results finding a 374 significant increase in the concentration of the supplement-specific bacteria BB-12, following ten 375 days of BB-12 supplementation. Importantly, as reported in adults, these results were temporary. 376 On Day 30 (20 days following the termination of the BB-12 supplementation), there were no significant differences in the concentration of BB-12 in the S2+BB12 group. 377

378 As yogurts and other dairy products commonly supplemented with probiotics often 379 possess other beneficial characteristics, such as a high calcium content, these properties of 380 probiotics could allow consumers to benefit from the nutritional components without risking 381 disruption to their microbiota and health. This potential beneficial shift to probiotic-associated 382 bacteria that we demonstrated in the S2+BB12 group (Figure 3) supports the theory that a 383 probiotic intervention may provide a net positive contribution to the gut microbiome ecosystem 384 without conferring strong effects on specific individual bacteria. These findings are also 385 consistent with the concept of emergent properties which postulates that individual properties

cannot entirely be explained by their individual components. [43] Therefore, in the context of the
current study, although no significant differences following the interventions were observed,
there was a global shift towards the increase of bacteria belonging to *Bifidobacterium* and *Lactobacillus* genera, commonly used probiotics. The combined effects of these bacteria could
have more functional implications and protective effects than individual bacterial changes
supporting the use of probiotics to prevent gastrointestinal disorders in children, although more
research is needed to validate this notion.

393 Species belonging to *Bifidobacterium* genus were highly abundant in both groups at the 394 three time points. Bifidobacteria are highly represented in children, as they use milk 395 oligosaccharides as a carbon source and to restrict human milk oligosaccharides availability to 396 other microorganisms [44]. In addition to the parent study findings, our metagenomic approach allowed a low-level taxonomic affiliation, revealing differences among species belonging to the 397 398 same genus as in the case of Bifidobacterium. It explains why Bifidobacterium genus was not 399 among the differentially abundant species in the previous study, *i.e.*, because different 400 *Bifidobacterium* species were abundant in the experimental group (S2+BB12) and in the control 401 group S2 (e.g., B. catenulatum, B. pseudocatenulatum). Additionally, this metagenomic approach 402 adds to the existing literature of the genomic potential of the microbial community underlying 403 microbiome-host interactions.

Because the fecal metabolome is influenced by different factors, these changes could
reflect shifts of dietary intake, digestion, microbial degradation, and host absorption. When we
analyzed the fecal metabolome and microbial diversity using both participant groups, we found
associations between metabolites (*e.g.*, uracil, deoxycarnitine, and thymine) and microorganisms.
Uracil was positively associated with Clostridiales family, *A. finegoldii, B. animalis*, and *E*.

409 rectale. B. dorei, F. plautii, Enterobacteriaceae family, and E. coli were negatively correlated 410 with uracil. During infections, the immune response triggered by uracil promotes pathogen 411 bacteria elimination, intestinal cell repair, and host homeostasis. [45] Thymine was positively 412 associated with L. delbrueckii, the probiotic used in both interventions, and negatively correlated 413 to F. plautii. Thymine was found to accelerate microbial metabolisms and ROS production 414 improving antibiotic efficacy both in vitro and in vivo. [46] Deoxycarnitine, positively associated 415 with S. thermophilus, was linked to increased intestinal permeability. [47] This suggests that the 416 fecal metabolome may influence gut immune function, permeability, and homeostasis. 417 A strength of our study is that it was a randomized, blinded controlled trial conducted on 418 children ages one to five years old, an age group that is rarely studied in probiotic research. 419 Additionally, we incorporated and integrated both metagenomic and metabolomic analyses to 420 characterize the effect of BB-12 supplemented yogurt on the children's gut-microbiome and 421 metabolism. This unique integration allowed us to test more system-wide and functional effects 422 on the gut microbiome as a result of two probiotic interventions, providing more comprehensive 423 data on gut health. However, this study examined short-term changes of probiotics over a ten-day 424 period, and more studies should be conducted to investigate the long-term effects on probiotic 425 consumption in this age group. Additionally, we did not incorporate information of dietary intake 426 in the current analysis. 427 More studies are needed to elucidate the mechanistic pathways by which probiotics such 428 as BB-12 can affect mucosal barrier functions and innate immunity. Future studies should

429 expand upon the findings presented in this double-blinded, randomized controlled trial and

430 examine the interplay of diet and probiotics on metabolites and microbiota in children.

431 Additionally, further research is needed to investigate environmental factors that influence the

432 impacts of probiotics on children's health status and behavior. The long-term supplementation
433 BB-12 on this population and its longitudinal effects during development should also be
434 examined. This would allow for more in-depth knowledge of the impact that probiotics have on
435 gut microbial communities in developing children as they age. Additionally, future research in
436 children at risk for gastrointestinal disorders may elucidate if these functional metabolite changes
437 as a result of S2+BB12 probiotic intervention confer a protective gastrointestinal effect.

438 In conclusion, the results from this deep metagenomic and metabolomic characterization 439 of the gut microbiome and metabolome of children following BB-12 consumption did not show 440 significant differences between the groups, although net positive emergent property effects were 441 witnessed in the S2+BB12 group over time. The functional redundancy in healthy microbial 442 systems and metabolic stability reflects no changes in the microbial diversity, although we did 443 observe a separation effect in the S2+BB12 group as a result of the three-strain intervention 444 when we focused on probiotic-associated and beneficial bacteria reported the literature. Our 445 study validated previous results from Tan et. al and allowed a more in-depth taxonomic 446 characterization of the microorganisms, their genes, and their metabolites. We detected higher 447 abundances of two of the probiotic intervention bacterial taxa (B. animalis and S. thermophilus) 448 in study subjects receiving the based S2 probiotic intervention + BB12, but no individual 449 taxonomic changes occurred in the S2 only group. Finally, although we did not see global fecal 450 metabolome response to either probiotic, several fecal metabolites were decreased in the 451 S2+BB12 group, indicating a net functional impact of the addition of BB12 to the probiotic 452 intervention. Future research replicating these results across different patient populations will 453 confirm the therapeutic use of BB12 as a probiotic intervention to exert beneficial impacts on the 454 pediatric gastrointestinal system.

455

456 Materials and Methods

457 Study Design, Participants, and Setting

458 Participants ages one to five years old were recruited through the Capital Area Primary 459 Care Research Network for phase I of a double-blinded, randomized controlled study (protocol 460 NCT001652287). Participants included in this study were children whose parents/caregivers 461 were able to read, write, and speak either English or Spanish and had access to a telephone and 462 refrigerator. Eligible participants provided written informed consent were enrolled and 463 randomized as described by Tina et al to either the BB-12[®] or control yogurt drink by family 464 cluster. The study protocol was approved by the Georgetown University Institutional Review 465 Board (IRB No. 2012-1112, Washington, DC). The independent Data Safety Monitoring Board 466 reviewed the protocol before study initiation and checked adverse event data at approximately 467 33%, 50% and 66% data completion. Additional monitoring was conducted by the FDA/CBER, 468 under IND#13691 and the National Institutes of Health (NIH), National Center for 469 Complementary and Integrative Health (NCCIH), including its Office of Clinical and Regulatory 470 Affairs. Participants' eligibility criteria are described in Tan et al., [30] which included the 471 absence of lactose intolerance and chronic conditions, such as diabetes and asthma. The 472 participants were asked not to consume any products containing probiotics for 14 days before 473 initiating the yogurt intervention and throughout the entire intervention period. The base yogurt 474 was prepared with live starter cultures of *Streptococcus thermophilus* and *Lactobacillus* 475 delbrueckii probiotics (referred to as the two strain [S2] yogurt group), as described in Tan et al. 476 [30]. At baseline, the children were randomized into two groups called S2 or S2+BB12. 477 Participants in the S2 group (n = 31) were administered 112 g of the base yogurt beverage 478 (containing Streptococcus thermophilus and Lactobacillus delbrueckii only). In contrast,

479	participants	in the	e S2+BB12	group (n	1 = 28	were administered	the	base y	ogurt	beverage.	with
1/2	puritivipunto			Eloup (II	I = 20			UUDU 1	102uit	our or use,	VV 1 L

- 480 additional 1×10^{10} colony-forming units of BB12 per serving per day. The yogurt was
- 481 administered to the participants for ten consecutive days.
- 482 Sample Collection and Processing

483 Fecal samples were collected at baseline (*Day 0*), following ten days of yogurt

484 consumption (*Day 10*), and 20 days following discontinuation of yogurt administration (*Day 30*),

485 and immediately stored after collection at -80 °C. Samples from days zero, ten and 30 were then

thawed, and approximately 100 mg of the samples were sent to Microbiome Center of the

487 Children's Hospital of Philadelphia (n = 169) for microbiome analysis and another 100mg were

488 sent to Metabolon Inc. (Morrisville, NC, USA; n = 174) for metabolomic analyses.

489 Metagenomic profiling

490 The DNA used for the metagenomic analysis was extracted using the DNeasy PowerSoil 491 Kit (Qiagen, Hilden, Germany) and quantified with the Quant-iT PicoGreen Assay Kit 492 (Molecular Probes). Shotgun libraries were generated from 0.5ng DNA using the Nextera XT 493 Library Prep Kit (Illumina, San Diego, CA, USA) and libraries were sequenced on an Illumina 494 HiSeq 2500 in High Output mode to produce paired-end 125bp sequence reads. Extraction 495 blanks and nucleic acid-free water were processed along with experimental samples to 496 empirically assess environmental and reagent contamination. A laboratory-generated mock 497 community consisting of DNA from Vibrio campbellii and Lambda phage was included as a 498 positive sequencing control.

499 Metabolomic analysis

The metabolomic analysis was performed using untargeted ultra-performance liquid
 chromatography-tandem mass spectrometry (UPLC/MS/MS, Waters ACQUITY, Milford, MA,

502 USA), as described previously [48]. Briefly, the fecal samples were prepared using the 503 automated MicroLab STAR system (Hamilton Company, Franklin, MA, USA) and extracted at a 504 constant per-mass basis. Proteins were removed using methanol precipitation (Glen Mills 505 GenoGrinder 2000), followed by centrifugation. The samples were processed using four 506 methods: reverse phase (RP)-UPLC/MS/MS with electrospray ionization (ESI), in both positive 507 (optimized for hydrophilic and hydrophobic compounds, respectively) and negative modes, and 508 hydrophilic interaction chromatography (HILIC)-UPLC/MS/MS-ESI in negative ion mode. The 509 raw UPLC/MS/MS data were integrated into ion peaks organized by mass, retention time/index, 510 and peak area. Metabolites were annotated by comparison of individual spectra to a standard 511 reference library, and area-under-the-curve analysis was performed for peak quantification. 512 Statistical Analysis 513 For gut microbiome and metabolome analyses, we studied within and between group 514 differences after ten days of probiotic consumption (Day 10) and 20 days post probiotic 515 discontinuation (Day 30). Shotgun metagenomic data were analyzed using Sunbeam. [49] The 516 abundance of bacteria was estimated using Kraken. [50] Taxa that were above 0.1% abundance 517 in any sample were used for differential abundance testing, and differential abundance analysis 518 was performed using linear models of Log₁₀ transformed relative abundances. Reads were 519 mapped to the KEGG database [51] using Diamond [52] to estimate the abundance of bacterial 520 gene orthologs. Alpha diversity within samples in the S2 and S2+BB12 groups were assessed by 521 computing the expected number of species at a sequencing depth of 1,000 reads and the Shannon 522 index. To evaluate community-level differences between S2 and S2+BB12 group fecal samples, 523 beta diversity was calculated using Bray-Curtis dissimilarity matrices, visualized using Principal

524 Coordinates Analysis (PCoA) plots, and relationships within and between S2 and S2+BB12
525 groups were compared using the PERMANOVA test.

526 The top 25 most abundant bacterial taxa and gene orthologs from shotgun metagenomics 527 sequencing were selected using linear models to evaluate the taxa with greatest estimated change 528 in Log₁₀ transformed relative abundance for the given comparison. Probiotic-associated bacteria, 529 previously demonstrated to be short chain fatty acid (SCFA)-producers and beneficial for GI 530 health, [53] were determined from the literature (Supplemental Table 2). The impact of the S2 vs. 531 S2+BB12 probiotic strains on overall probiotic-associated bacterial relative abundance was 532 additionally measured and visualized by CANOCO version 5 [54] in a post-selection PCA to 533 evaluate the effect of targeted probiotic strain administration on bacterial responses of taxa 534 known to be linked to gut microbiome health. 535 Exploratory and hypothesis-driven metabolite analyses were performed with untargeted 536 metabolite data processed by Metabolon Inc. using MetaboAnalyst 5.0 537 (https://www.metaboanalyst.ca/)[55] and R. [56] Metabolites with 20% or more missing values 538 were excluded from the exploratory analyses. Missing values, if any, were imputed as 1/5 of the 539 minimum positive value of each feature. Metabolite values were median-scaled and Log₁₀ 540 transformed. Wilcoxon rank-sum test, fold change (FC) analyses (FC threshold = 2), and 541 Principal Component Analysis (PCA) were performed to analyze differences between Day 0 vs. 542 Day 10, Day 0 vs. Day 30, and Day 0 vs. Day 30 within the S2 and S2+BB12 groups and between groups within each time point. 543 544 Hypothesis-driven metabolite analyses were additionally performed in metabolites 545 associated with the amino acid super pathways (*i.e.*, glycine, serine and threonine metabolism,

546 alanine and aspartate metabolism, etc.), and SCFAs, as these metabolites are strongly associated

547 with gut microbial community characteristics. [9] Linear mixed-effects model followed by post 548 hoc pairwise testing (when appropriate) and Tukey's correction were performed in JMP 549 statistical analysis platform. [57] 550 To create a network of metabolite-taxa correlation pairs, filtering was applied to 551 metabolites as above as well as restricting to bacterial substrates and products based on previous 552 work [58]. Briefly, metabolite substrates were defined as those that were increased after 553 treatment with antibiotics and products were those that decreased. [38] Microbial taxa at the 554 species level were filtered to include taxa present at > 0.01% mean relative abundance and taxa 555 that changed in the S2+BB12 treatment group (i.e., Lactobacillus delbrueckii, Streptococcus 556 thermophilus, and BB-12). Spearman correlation testing was then performed on each microbe-557 metabolite pair with FDR correction applied to p-values. Network diagrams of bacteria and 558 metabolites were generated using Cytoscape v3.9.1. [59] Metabolites that significantly correlated 559 with L. delbrueckii, S. thermophilus, and BB-12 were additionally tested for intervention-560 associated change over time. Statistical significance was defined as p-values or FDR corrected p-561 values < .05 for all statistical analyses. 562 563 564 565 566 567 568 569

570 Figures and Tables:

- 571 Figure 1AB = Study Design and Intervention
- 572 Figure 2AJ = Metagenomic results
- 573 Figure 3AD = Other Probiotics Comparison
- 574 Figure 4 AF = Metabolite Volcano Plots
- 575 Figure 5AN = Selected Metabolites Analysis
- 576 Figure 6 = Heatmap Microbiome/Metabolome
- 577 Figure 7AB = Network Analysis (Metagenomics/Metabolomics) 578
- 579 Figure S1 = Metagenomics PCoA Day 30
- 580 Figure S2 = Metabolite PCA
- Table 1 = Participants Demographics582
- 583 Supplemental table 1 = Top_25_linear_model_KEGG
- 584 Supplemental table 2 = Probiotics selection
- 585 Supplemental table 3 = Metabolites and Pathways Volcano plot
- 586 Supplemental table 4 = Selected_metabolite_model_results
- 587 Supplemental table 5 = Table_S5_26_taxa_to_479_metab_correlations
- 588 Supplemental table 6 = Table_S6_26_taxa_to_79_metab_network
- 589
- 590 Acknowledgements: The authors would like to thank Dr. Joan Austin for her review and edits
- and Dr. Jennifer J. Barb for bioinformatics consultative support. A special thanks to the
- 592 participants of this study and the Georgetown Microbiome Group.

593 Author contributions:

- 594 Concept and design: Drs. Merenstein and Joseph
- 595 Acquisition of data, sample processing: Tan, Dr. Merenstein, Ms. Franks, Ms. Brooks

596 Statistical Analysis, or interpretation of data: Dr. Vizioli, Ms. Franks, Dr. Daniel, Dr. Bittinger,

- 597 Dr. Jaime-Lara, Dr. Maki, Dr. Joseph
- 598 Drafting of the manuscript: Dr. Vizioli, Dr. Diallo, Ms. Franks, Ms. Brooks, Dr. Jaime-Lara, Dr.
 599 Maki, Dr. Joseph
- 600 Critical revision of the manuscript for important intellectual content: Dr. Diallo, Dr. Merenstein,
- 601 Dr. Tan, Brooks, Dr. Joseph, Dr. Scott, Dr. Bittinger

- 602 Administrative, technical, or material support: Dr. Joseph
- 603 Obtained funding: Drs. Joseph & Merenstein
- 604 Study supervision: Drs. Merenstein & Joseph
- 605 **Competing interest declaration**: D.J.M. previously served as a paid expert Howard University
- and Bayer. D.J.M. has done legal work for Visniome VSL#3, Golo for Life and President of the
 International Scientific Association for Probiotics and Prebiotics (ISAPP) board. The remaining
- 608 authors have no conflicts of interest to declare.
- Role of study sponsors: The funding sources had no role in the design and conduct of the study;
 collection, management, analysis, and interpretation of the data; preparation, review, or approval
- 611 of the manuscript; and decision to submit the manuscript for publication.
- 612 **Funding/support:** PVJ is supported by National Institute of Alcohol Abuse and Alcoholism
- under award number, Z01AA000135, the National Institute of Nursing Research and the
- 614 Rockefeller University Heilbrunn Nurse Scholar Award. PVJ is supported by the Office of
- 615 Workforce Diversity, and the Office of Workforce Diversity, National Institutes of Health
- 616 Distinguished Scholar Program. Intramural Research Training Award (to ATF, RJL, and BEB).
- 617 RJL is supported by the Center of Compulsive Behaviors Fellowship, National Institutes of
- Health. Funding from Dannon to Tan, T.P., & Merenstein, D.J., the Department of Family
- 619 Medicine, Georgetown University Medical Center, Washington, DC. KAM is supported by
- 620 intramural research funds at the National Institutes of Health, Clinical Center.
- 621 **Data availability:** All data produced in the present study are available upon reasonable request
- to the authors. Data was also submitted to SRA under project number PRJNA929986.
- 623 Author's Note: The content is solely the responsibility of the authors and does not necessarily
- 624 represent the official views of the National Institutes of Health.

625 **References**

- Wang, W.L., et al., *Application of metagenomics in the human gut microbiome.*World J Gastroenterol, 2015. **21**(3): p. 803-14.
- Bäckhed, F., et al., *Dynamics and Stabilization of the Human Gut Microbiome during the First Year of Life.* Cell Host Microbe, 2015. **17**(5): p. 690-703.
- Substantiation
 <
- Mayer-Davis, E.J., et al., *Breast-feeding and risk for childhood obesity: does maternal diabetes or obesity status matter*? Diabetes Care, 2006. 29(10): p.
 2231-7.
- 636 5. Yatsunenko, T., et al., *Human gut microbiome viewed across age and geography.* Nature, 2012. **486**(7402): p. 222-7.
- 638 6. Jungersen, M., et al., *The Science behind the Probiotic Strain Bifidobacterium* 639 *animalis subsp. lactis BB-12((R)).* Microorganisms, 2014. **2**(2): p. 92-110.
- Kostic, A.D., et al., *The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes.* Cell Host Microbe,
 2015. **17**(2): p. 260-73.
- 6438.Stiemsma, L.T. and K.B. Michels, The Role of the Microbiome in the644Developmental Origins of Health and Disease. Pediatrics, 2018. 141(4).
- 645 9. Neis, E.P., C.H. Dejong, and S.S. Rensen, *The role of microbial amino acid* 646 *metabolism in host metabolism.* Nutrients, 2015. **7**(4): p. 2930-46.
- Stinson, L.F., M.S. Payne, and J.A. Keelan, *Planting the seed: Origins, composition, and postnatal health significance of the fetal gastrointestinal microbiota.* Crit Rev Microbiol, 2017. 43(3): p. 352-369.
- 65011.Boulangé, C.L., et al., Impact of the gut microbiota on inflammation, obesity, and651metabolic disease. Genome Med, 2016. 8(1): p. 42.
- Hill, C., et al., *Expert consensus document. The International Scientific*Association for Probiotics and Prebiotics consensus statement on the scope and
 appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol, 2014.
 11(8): p. 506-14.
- Hojsak, I., et al., *Guidance on the use of probiotics in clinical practice in children with selected clinical conditions and in specific vulnerable groups.* Acta Paediatr,
 2018. **107**(6): p. 927-937.
- 659 14. Plaza-Diaz, J., et al., *Mechanisms of Action of Probiotics*. Adv Nutr, 2019.
 660 **10**(suppl_1): p. S49-s66.
- Moroni, O., et al., *Inactivation of adhesion and invasion of food-borne Listeria monocytogenes by bacteriocin-producing Bifidobacterium strains of human origin.* Applied and Environmental Microbiology, 2006. **72**(11): p. 6894-6901.
- Srutkova, D., et al., *Bifidobacterium longum CCM 7952 Promotes Epithelial Barrier Function and Prevents Acute DSS-Induced Colitis in Strictly Strain- Specific Manner.* PLoS One, 2015. **10**(7): p. e0134050.
- Schroeder, B.O., et al., *Bifidobacteria or Fiber Protects against Diet-Induced Microbiota-Mediated Colonic Mucus Deterioration*. Cell Host Microbe, 2018.
 23(1): p. 27-40.e7.

670 671 672	18.	Artis, D., <i>Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut.</i> Nature Reviews Immunology, 2008. 8 (6): p. 411-
673	10	Xue Let al Prohiotics may delay the progression of populcoholic fatty liver
674	13.	disease by restoring the gut microbiota structure and improving intestinal
675		endotoxemia Sci Rep 2017 7: p 45176
676	20	Sharma R et al. Psychobiotics: The Next-Generation Probiotics for the Brain
677	20.	Curr Microbiol 2021 78 (2): p 449-463
678	21	Mörkl S et al Probiotics and the Microbiota-Gut-Brain Axis: Focus on
679		<i>Psychiatry</i> . Curr Nutr Rep. 2020. 9 (3): p. 171-182.
680	22.	Savignac, H.M., et al., Bifidobacteria modulate cognitive processes in an anxious
681		<i>mouse strain.</i> Behav Brain Res, 2015. 287 : p. 59-72.
682	23.	Griffin, S.M., et al., Restorative effects of probiotics on memory impairment in
683		sleep-deprived mice. Nutr Neurosci, 2022: p. 1-11.
684	24.	Suez, J., et al., The pros, cons, and many unknowns of probiotics. Nat Med,
685		2019. 25 (5): p. 716-729.
686	25.	Wilkins, T. and J. Sequoia, Probiotics for Gastrointestinal Conditions: A Summary
687		of the Evidence. Am Fam Physician, 2017. 96(3): p. 170-178.
688	26.	Merenstein, D., et al., Bifidobacterium animalis subsp. lactis BB-12 Protects
689		against Antibiotic-Induced Functional and Compositional Changes in Human
690		<i>Fecal Microbiome.</i> Nutrients, 2021. 13 (8): p. 2814.
691	27.	Suez, J., et al., Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is
692		Impaired by Probiotics and Improved by Autologous FMT. Cell, 2018. 174 (6): p.
693		1406-1423.e16.
694	28.	McKean, J., et al., Probiotics and Subclinical Psychological Symptoms in Healthy
695		Participants: A Systematic Review and Meta-Analysis. J Altern Complement
696		Med, 2017. 23 (4): p. 249-258.
697	29.	Łukasik, J., S. Salminen, and H. Szajewska, Rapid review shows that probiotics
698		and fermented infant formulas do not cause d-lactic acidosis in healthy children.
699		Acta Paediatr, 2018. 107 (8): p. 1322-1326.
700	30.	Tan, T.P., et al., Safety of Bifidobacterium animalis Subsp. Lactis (B. lactis)
701		Strain BB-12-Supplemented Yogurt in Healthy Children. J Pediatr Gastroenterol
702	0.4	Nutr, 2017. 64 (2): p. 302-309.
703	31.	Arpaia, N., et al., Metabolites produced by commensal bacteria promote
704	20	peripheral regulatory 1-cell generation. Nature, 2013. 504 (7480): p. 451-5.
705	32.	LeBlanc, J.G., et al., Beneficial effects on nost energy metabolism of snort-chain
706 707		Tatty acids and vitamins produced by commensal and problotic bacteria. Microb
707	22	Cell Faci, 2017. 10(1): p. 79. Conten M.A. and A.B. Bird. The Impact of Dist and Lifestule on Cut Misrobists
708	<i>აა</i> .	conion, M.A. and A.R. Bild, The Impact of Diet and Lifestyle on Gut Microbiota
709	34	Doi 7 L C Wu and W X Zhu Amino acid motabolism in intestinal bactoria:
710	54.	links botwoon gut ocology and best boalth. Front Biosci (Landmark Ed), 2011
712		16 n 1768-86
713	35	den Besten G et al. The role of short-chain fatty acids in the internlay between
714	00.	diet. gut microbiota, and host energy metabolism. Journal of Linid Research
715		2013. 54 (9): p. 2325-2340.
110		

Lee, S.H., et al., The Therapeutic Effect of a Multistrain Probiotic on Diarrhea-716 36. 717 Predominant Irritable Bowel Syndrome: A Pilot Study. Gastroenterol Res Pract, 718 2018. 2018: p. 8791916. 719 37. Riekeberg, E. and R. Powers, New frontiers in metabolomics: from measurement 720 to insight. F1000Res, 2017. 6: p. 1148. 721 38. Tanes, C., et al., Role of dietary fiber in the recovery of the human gut 722 microbiome and its metabolome. Cell Host Microbe, 2021. 29(3): p. 394-407.e5. 723 39. Kumbhare, S.V., et al., Factors influencing the gut microbiome in children: from 724 infancy to childhood. J Biosci, 2019. 44(2). 725 40. Laursen, M.F., et al., Administration of two probiotic strains during early 726 childhood does not affect the endogenous gut microbiota composition despite 727 probiotic proliferation. BMC Microbiology, 2017. 17(1): p. 175. 728 Wang, S., et al., A randomized, double blind, parallel, placebo-controlled study to 41. 729 investigate the efficacy of Lactobacillus paracasei N1115 in gut development of 730 young children. Food Sci Nutr, 2021. 9(11): p. 6020-6030. 731 42. Khalesi, S., et al., A review of probiotic supplementation in healthy adults: helpful 732 or hype? European Journal of Clinical Nutrition, 2019. 73(1): p. 24-37. 733 43. Ponge, J.F., Emergent properties from organisms to ecosystems: towards a 734 realistic approach. Biol Rev Camb Philos Soc, 2005. 80(3): p. 403-11. 735 44. Turroni, F., D. van Sinderen, and M. Ventura, Genomics and ecological overview 736 of the genus Bifidobacterium. Int J Food Microbiol, 2011. **149**(1): p. 37-44. 737 Lee, K.A., et al., Bacterial-derived uracil as a modulator of mucosal immunity and 45. 738 gut-microbe homeostasis in Drosophila. Cell, 2013. 153(4): p. 797-811. 739 Liu, Y., et al., Thymine Sensitizes Gram-Negative Pathogens to Antibiotic Killing. 46. 740 Frontiers in Microbiology, 2021. 12. 741 47. Ghonimy, A., et al., The Impact of Carnitine on Dietary Fiber and Gut Bacteria 742 Metabolism and Their Mutual Interaction in Monogastrics. Int J Mol Sci, 2018. 743 **19**(4). 744 48. Vizioli, C., et al., Untargeted Metabolomic Approach Shows No Differences in 745 Subcutaneous Adipose Tissue of Diabetic and Non-Diabetic Subjects 746 Undergoing Bariatric Surgery: An Exploratory Study. Biol Res Nurs, 2021. 23(1): 747 p. 109-118. 748 49. Clarke, E.L., et al., Sunbeam: an extensible pipeline for analyzing metagenomic 749 sequencing experiments. Microbiome, 2019. 7(1): p. 46. 750 Wood, D.E. and S.L. Salzberg, Kraken: ultrafast metagenomic sequence 50. 751 classification using exact alignments. Genome Biol, 2014. 15(3): p. R46. 752 Ogata, H., et al., KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic 51. 753 Acids Res, 1999. 27(1): p. 29-34. Buchfink, B., C. Xie, and D.H. Huson, Fast and sensitive protein alignment using 754 52. 755 DIAMOND. Nat Methods, 2015. 12(1): p. 59-60. 756 53. Markowiak-Kopeć, P. and K. Śliżewska, The Effect of Probiotics on the 757 Production of Short-Chain Fatty Acids by Human Intestinal Microbiome. 758 Nutrients, 2020. **12**(4). 759 54. Braak, C.t. and P. `milauer, CANOCO Reference Manual and User's Guide to 760 Canoco for Windows: Software for Canonical Community Ordination (Version 4). 761 1998.

- 55. Chong, J., et al., *MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis.* Nucleic Acids Res, 2018. 46(W1): p. W486-w494.
 56. R Development Core Team, *R: A language and environment for statistical computing.* 2013, R Foundation for Statistical Computing: Vienna, Austria.
 57. Ye, C., et al., *Design of experiment and data analysis by JMP*®(SAS institute) in analytical method validation. Journal of pharmaceutical and biomedical analysis,
- 768 2000. **23**(2-3): p. 581-589.
- Tanes, C., et al., *Role of dietary fiber in the recovery of the human gut microbiome and its metabolome.* Cell host & amp; microbe, 2021. 29(3): p. 394407.e5.
- 59. Shannon, P., et al., *Cytoscape: a software environment for integrated models of biomolecular interaction networks*. Genome Res, 2003. **13**(11): p. 2498-504.